CARMENTA: The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01559467
Collaborator
Dutch Heart Foundation (Other)
300
1
3
62.6
4.8

Study Details

Study Description

Brief Summary

Approximately half of patients with acute chest pain, a very common reason for emergency department visits worldwide, have a cardiac cause. Two-thirds of patients with a cardiac cause are eventually diagnosed with a so-called non-ST-elevation myocardial infarction. The diagnosis of non-ST-elevation myocardial infarction is based on a combination of symptoms, electrocardiographic changes, and increased serum cardiac specific biomarkers (high-sensitive troponin T). Although being very sensitive of myocardial injury, increased high-sensitive troponin T levels are not specific for myocardial infarction. Invasive coronary angiography is still the reference standard for coronary imaging in suspected non-ST-elevation myocardial infarction. This study investigates whether non-invasive imaging early in the diagnostic process (computed tomography angiography (CTA) or cardiovascular magnetic resonance imaging (CMR)) can prevent unnecessary invasive coronary angiography. For this, patients will be randomly assigned to either one of three strategies: 1) routine clinical care and computed tomography angiography early in the diagnostic process, 2) routine clinical care and cardiovascular magnetic resonance imaging early in the diagnostic process, or 3) routine clinical care without non-invasive imaging early in the diagnostic process.

Condition or Disease Intervention/Treatment Phase
  • Other: Cardiovascular Magnetic Resonance Imaging
  • Other: Computed Tomography Angiography
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Supplementary Role of Cardiovascular Magnetic Resonance Imaging and Computed Tomography Angiography to Routine Clinical Practice in Suspected Non-ST Elevation Myocardial Infarction - A Randomized Controlled Trial
Study Start Date :
Apr 1, 2012
Actual Primary Completion Date :
May 1, 2017
Actual Study Completion Date :
Jun 19, 2017

Arms and Interventions

Arm Intervention/Treatment
Other: Routine clinical care plus early CMR

Other: Cardiovascular Magnetic Resonance Imaging
Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process

No Intervention: Routine clinical care

Other: Routine clinical care plus early CTA

Other: Computed Tomography Angiography
Routine clinical care plus computed tomography angiography early in the diagnostic process

Outcome Measures

Primary Outcome Measures

  1. Total number of patients with at least one invasive coronary angiography during initial admission [During initial hospital admission, an expected average of 7 days]

Secondary Outcome Measures

  1. Thirty-day clinical outcome (a composite of major adverse cardiac events [MACE] and major procedure related complications) [30 days]

  2. One-year clinical outcome (a composite of major adverse cardiac events [MACE] and major procedure related complications) [One-year]

  3. Quality of life [One-year]

  4. Cost-effectiveness [After study completion, expected after 3 years]

    The economic evaluation will be a cost-effectiveness analysis, with quality-adjusted life years (QALYs) as outcome measure. Effects will be calculated in terms of QALYs. To investigate the cost-effectiveness of the three strategies, incremental cost-effectiveness ratios (ICERs) will be calculated. Cost-effectiveness acceptability curves (CEACs) are derived in order to show the probability of each strategy being the optimal choice, for a range of possible maximum values a decision maker is willing to pay for a QALY.

  5. Cardiogoniometry [After study completion, expected after 3 years]

    A retrospective analysis will be performed to investigate whether CGM performed on the cardiac emergency department can differentiate between a coronary and non-coronary etiology in suspected NSTEMI

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Prolonged symptoms suspected of cardiac origin (angina pectoris or angina equivalent), and presentation on the cardiac emergency department <24 hours after symptom onset

  • Increased levels of high-sensitive Troponin-T (>14ng/L)

  • Age >18 years and <85 years

  • Willing and capable to give written informed consent

  • Written informed consent

Exclusion Criteria:
  • Ongoing severe ischemia requiring immediate invasive coronary angiography

  • Shock (mean arterial pressure < 60 mmHg) or severe heart failure (Killip Class ≥ III)

  • ST-elevation myocardial infarction (ST-elevation in 2 contiguous leads: ≥0.2mV in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads or new left bundle branch block)

  • Chest pain highly suggestive of non-cardiac origin:

  • Acute aortic dissection

  • Acute pulmonary embolism (high risk patient defined as Wells score >6)

  • Musculoskeletal or gastro-intestinal pain

  • Other (pneumothorax, pneumonia, rib fracture, etc.)

  • Previously known coronary artery disease, defined as:

  • Any non-invasive diagnostic imaging test positive for coronary artery disease

  • Coronary stenosis >50% on any previous invasive coronary angiography or computed tomography angiography

  • Documented previous myocardial infarction

  • Documented previous coronary artery revascularization

  • Known cardiomyopathy

  • Pregnancy

  • Life threatening arrhythmia on the cardiac emergency department or prior to presentation

  • Tachycardia (≥100/bpm)

  • Atrial fibrillation

  • Angina pectoris secondary to anemia (<5.6 mmol/L), untreated hyperthyroidism, aortic valve stenosis (aortic valve area ≤ 1.5 cm2), or severe hypertension (>200/110 mmHg)

  • Life expectancy <1 year (malignancy, etc.)

  • Contraindications to cardiovascular magnetic resonance imaging: metallic implant (vascular clip, neuro-stimulator, cochlear implant), pacemaker or implantable cardiac defibrillator, claustrophobia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Maastricht University Medical Center Maastricht Limburg Netherlands 6202 AZ

Sponsors and Collaborators

  • Maastricht University Medical Center
  • Dutch Heart Foundation

Investigators

  • Principal Investigator: Harry J Crijns, MD, PhD, Maastricht University Medical Center
  • Principal Investigator: Joachim Wildberger, MD, PhD, Maastricht University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01559467
Other Study ID Numbers:
  • NL37574.068.11 / METC 11-2-077
First Posted:
Mar 21, 2012
Last Update Posted:
Jul 5, 2017
Last Verified:
Jul 1, 2016

Study Results

No Results Posted as of Jul 5, 2017